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ABSTRACT
Background    The efficacy of adding target prostate 
biopsy (PBx) of suspected cancer lesions identified on 
magnetic resonance imaging (MRI) and/or transrectal 
ultrasonography (TRUS) to initial systematic PBx was 
evaluated. Moreover, the outcomes were compared be-
tween 2 physicians. 
Methods    We retrospectively investigated 238 pa-
tients who underwent first-time PBx in our hospital. 
All patients were examined with prostate MRI before 
PBx. Fourteen systematic biopsies were obtained in all 
patients. When a suspected lesion was present on MRI 
and/or TRUS, the lesion was the target of target PBx. 
Results    The overall detection rate of prostate cancer 
(PCa) was 45% (106/238). With target PBx, the PCa 
detection rate was 32% overall, while that of suspected 
lesions seen only on MRI was 32%, that of suspected le-
sions seen only on TRUS was 8% and that of suspected 
lesions seen on both MRI and TRUS was 52%. The 
same tendency was shown for each physician. Compar-
ing systematic PBx and target PBx, the overall rate of 
Gleason score (GS) upgrading with target PBx was 13%. 
The rate of PCa detected only by systematic PBx was 
95%. There was no significant difference between the 2 
physicians. 
Conclusion    In initial PBx, the addition of target PBx 
of suspected cancer lesions detected by MRI and/or 
TRUS to systematic PBx might not be useful to improve 
the cancer detection rate. However, it may enable more 
accurate risk classification and detection of minute can-
cers with a high GS. 
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The pathological diagnosis of prostate cancer (PCa) is 
based on the use of ultrasonography-guided prostate 
biopsy (PBx). Based on recent systematic reviews, 10 
to 12 cores are generally taken because they show bet-
ter efficacy for cancer detection than 6 cores.1 However, 
the cancer detection rate of PBx has traditionally been 
fraught with poor sensitivity, around 50%.2 Many meth-
odologies, techniques and approaches are used to im-
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prove this situation. However, no dramatic improvement 
of the cancer detection rate has been achieved. Accord-
ingly, the best methodology for PBx remains controver-
sial. 
 On the other hand, progress in imaging modalities, 
for example magnetic resonance imaging (MRI) and 
transrectal ultrasonography (TRUS), has been remark-
able in recent years. MRI has developed particularly 
rapidly in the past 20 years, along with the management 
of localized PCa. A high diagnostic accuracy has been 
reported using various groups of patients and protocols. 
Many reports have suggested that the rate of PCa detec-
tion was improved by combining MRI findings with a 
PBx.3–6 However, there are also reports that deny the 
usefulness of MRI in PBx.7, 8 Currently, as the method-
ology of PBx has progressed, the detection rate of the 
MRI/US fusion biopsy system has been reported.9, 10 
However, since such systems are very expensive, at the 
moment, use of this approach has not become wide-
spread. 
 Although past studies have focused on methodolo-
gies of PBx, to the best of our knowledge, no papers 
have examined the difference in outcomes with differ-
ent operators who performed the PBx using the same 
methodology and instrument. Therefore, the aim was 
to evaluate the efficacy of the addition of target PBx of 
suspected cancer lesions detected by MRI and/or TRUS 
to a systematic, 14-core, transrectal ultrasound-guided 
PBx. Moreover, the outcomes of the PBx performed by 2 
physicians who used the same methodology and instru-




This study was approved by the Ethics Committee of 
Tottori University, Japan, and all patients provided their 
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Table 1. Patients’ characteristics  
   Comparison between 2 physicians
Patients characteristics Overall Physician X Physician Y P value
Number of patients 238  137  101
Age, mean [range], year 69.2 [39–93] 69.6 [42–86] 68.5 [39–93] 0.40
PSA, mean [range], ng/mL 9.60 [3.27–29.63] 9.03 [3.27–24.63] 10.57 [3.48–29.63] 0.12
Prostate volume, mean [range], mL 45.8 [14–231] 45.6 [14–231] 46.3 [14–158] 0.84
PSAD, mean [range], ng/mL/mL 0.25 [0.04–1.34] 0.23 [0.04–0.83] 0.28 [0.07–1.34] 0.26
Number of patients with target PBx (%) 188  (79%) 104 (76%) 84 (83%) 0.29
 PBx, prostate biopsy; PSA, prostate-specific antigen; PSAD, PSA density.
written, informed consent. A total of 333 patients with 
elevated prostate-specific antigen (PSA) who underwent 
first-time PBx at the Department of Urology, Tottori 
University Hospital, between November 2010 and Feb-
ruary 2013, were retrospectively investigated. Patients 
whose PSA level was less than 4 ng/mL or more than 30 
ng/mL and who underwent 1 or more previous PBx pro-
cedures were excluded. Thus, 238 patients were included 
in the final analysis. All patients were examined with 
prostate MRI before undergoing PBx. All PBx proce-
dures were performed within 4 weeks after MRI.
 
MRI protocol 
In our hospital, we used a 1.5-T (Achieva, Philips 
Healthcare, Best, Netherlands) or a 3.0-T (MAGNETOM 
skyra, Siemens, Munich, Germany) magnetic reso-
nance imaging (MRI) system. All patients underwent 
diffusion-weighted imaging (DWI), apparent diffusion 
coefficient (ADC) mapping and dynamic imaging, in 
addition to the imaging sequences as part of a routine 
prostate MRI protocol. T2-weighted images (T2WI) 
were acquired in 3 orthogonal planes (axial, sagittal and 
coronal). All images were reviewed by radiologists blind 
to the PSA data. Lesions were defined as suspected 
cancer lesions on MRI if 2 or more of the following 4 
findings were present: i) low-intensity on T2WI; ii) high-
intensity on DWI; iii) low-intensity on the ADC map 
and iv) enhancement in the early phase but washed out 
on dynamic imaging.
 
Transrectal PBx protocol 
All biopsies were obtained under TRUS guidance using 
a medical ultrasonography scanner (Nemio XG, Toshi-
ba, Tokyo, Japan). PBx was performed by 2 physicians, 
Physician X, a urologist in his 6th year, and Physician Y, 
a urologist in his 5th year, using the same methodology 
and instruments, under caudal anesthesia with an 18-G 
biopsy needle (BARD Max-Core Disposable Core Bi-
opsy Instrument, Tempe, AZ). Lesions were defined as 
suspected cancer lesions on TRUS if low-echoic lesions 
were identified by the operators. The judgment of a sus-
pected cancer lesion on TRUS was left to each operator’s 
discretion. Fourteen systematic biopsies (8, peripheral 
zone; 4, transitional zone; 2, apex) were obtained in all 
patients. The systematic biopsy was performed indepen-
dently of the location of the suspected lesion on MRI 
and/or TRUS. When a suspected lesion was present on 
MRI and/or TRUS, that lesion was made a target PBx in 
addition to the systematic biopsy. If the suspected lesion 
on MRI could not be identified on TRUS, the target PBx 
was performed using only anatomical landmarks (shape 
of the prostate, position of the verumontanum, distance 
from the apex or the prostate base, presence of a benign 
cyst or calcification nearby, etc.). In target PBx, on prin-
ciple, 1 core was taken from 1 suspected lesion (Fig. 1).
   
Statistical analyses 
All statistical analyses were performed using PASW 
statistics 18 (SPSS, Chicago, IL). Statistical analysis was 
performed with the chi-square test for continuous vari-
ables. Fisher’s exact test was used to compare categori-
cal variables. P-values of less than 0.05 were considered 
significant.  
   
RESULTS
Patients’ characteristics 
The characteristics of the patients in each physician’s 
Fig. 1. Transrectal prostate biopsy was performed as follows. 
Fourteen systematic biopsies (8, peripheral zone; 4, transitional 
zone; 2, apex) were obtained in all patients. When a suspected le-
sion was present on MRI and/or TRUS, it was targeted for biopsy, 
in addition to the systematic biopsy. MRI, magnetic resonance im-
age; TRUS, transrectal ultrasound.
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Table 3. The cancer detection rate of target PBx by imaging modality
   Comparison between 2 physicians
Image modality in target PBx Overall Physician X Physician Y P value
 Number of patients (%) 188/ 238 (79%) 104/ 137 (76%) 84/ 101 (83%) –
Total (%) 61/ 188 (32%) 27/ 104 (26%) 34/ 84 (40%) 0.04*
Only on MRI (%) 23/ 73 (32%) 4/ 17 (24%) 19/ 56 (34%) 0.42
Only on TRUS (%) 6/ 76 (8%) 3/ 50 (6%) 3/ 26 (11%) 0.39
On both MRI and TRUS (%) 38/ 73 (52%) 22/ 51 (43%) 16/ 22 (73%) 0.001**
 MRI, magnetic resonance imaging; PBx, prostate biopsy; TRUS, transrectal ultrasonography.
Table 2. The overall PBx outcome including both patients with and without target PBx
   Comparison between 2 physicians
PCa detection ratio Overall Physician X Physician Y P value
 Number  of patients 238 137 101 –
PCa (%) 106/ 238 (45%) 55/ 137 (40%) 51/ 101 (50%) 0.11
 Low GS (%) 21/ 106 (20%) 10/  55 (19%) 11/ 51 (22%) 0.62
 Moderate GS (%) 36/  106 (37%) 21/  55 (38%) 17/ 51 (34%) 0.65
 High GS (%) 47/  106 (43%) 24/  55 (43%) 23/ 51 (44%) 0.88
PCa with MRI suspicion (%) 89/  155 (58%) 43/  76 (57%) 46/ 79 (58%) 0.91
PCa with TRUS suspicion (%) 66/  138 (48%) 39/  95 (41%) 27/  43 (62%) 0.02*
 GS, Gleason score; MRI, magnetic resonance imaging; PBx, prostate biopsy; PCa, prostate cancer; TRUS, transrectal ultrasonography.
group are summarized in Table 1. Physician X’s group 
had 137 patients, and Physician Y’s group had 101 pa-
tients. The baseline characteristics of the patients in each 
group showed no significant differences in age, PSA lev-
els, prostate volume, PSA density (PSAD) and the rate 
of patients with target PBx.
 
The overall PBx outcome 
The overall outcomes of PBx are presented in Table 2. 
The overall detection rate of PCa including both patients 
with and without target PBx was 45% (106/238), and 
43% (47/106) of PCa patients was diagnosed as having 
a high Gleason score (GS) (4 + 4 = 8 or more). There 
were no significant differences between the 2 physi-
cian groups. The overall detection rate in patients with 
suspected lesions on MRI was 58% (89/155), while that 
on TRUS was 48% (66/138). (This was not related to 
whether PCa was identified with the target PBx.) In all 
groups, the cancer detection rate was higher in patients 
with suspected lesions on imaging modalities. Especially 
in patients with suspected lesions on MRI, the increase 
in the cancer detection rate was the highest in all groups, 
approximately 60%. However, the cancer detection rate 
of patients with a suspected lesion on TRUS was lower 
and showed a significant difference between the 2 physi-
cian groups (P = 0.02).
 
Target PBx outcome 
The outcomes of target PBx are presented in Table 3. 
Of a total of 238 patients, 188 (79%) underwent target 
PBx. The overall detection rate of PCa with target PBx 
was 32% (61/188). If the overall detection rate for each 
imaging modalities was compared, that of patients with 
a suspected lesion only on MRI was 32% (23/73), that of 
patients with a suspected lesion only on TRUS was 8% 
(6/76) and that of patients with a suspected lesion seen 
on both MRI and TRUS was 52% (38/73). However, if 
more than 1 suspected lesion were found in a prostate, 
Table 4. The rate of GS upgrading by the addition of target PBx to 
systematic PBx
  Comparison between 2 physicians
 Overall Physician X Physician Y P value
 GS upgraded in target PBx  8 / 61  2 / 27  6 / 34  0.22
                                  (%) (13%) (7%) (17%)
     Low  Moderate GS  3  1  2  –
     Moderate  High GS  0  0  0  –
     0  Moderate GS  2  1  1  –
     0  High GS  3  0  3  –
GS, Gleason score; PBx, prostate biopsy. 
they were counted respectively. The detec-
tion rate was highest if the suspected lesion 
appeared on both MRI and TRUS, while that 
of a lesion seen only on TRUS was the low-
est. As for the outcome in each physician’s 
group, the same overall tendency was seen. 
However, the total detection rate of target 
PBx (P = 0.04) and the detection rate with 
a suspected lesion seen on both MRI and 
TRUS (P = 0.001) were significantly different 
between the physician groups.
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Fig. 2. The detection rate was investigated according to the site from which PCa was detected. The overall rate of PCa detected only by 
systematic PBx, which therefore did not need target PBx, was 95%. Furthermore, PCa was also detected from one lobe contralateral to 
the other with a suspected cancer lesion on MRI or TRUS in approximately 20% of patients (18/89). PBx, prostate biopsy; PCa, prostate 
cancer; MRI, magnetic resonance imaging; TRUS, transrectal ultrasonography.
Comparison of systematic PBx and target PBx
In the cases in which PCa was detected by both system-
atic PBx and target PBx, the overall rate of GS upgrad-
ing with target PBx as compared with systematic PBx 
was 13%. There was no significant difference between 
the 2 physicians’ groups. Interestingly, in some cases 
PCa was detected only by target PBx but not by system-
atic PBx, including PCa with a high GS (4 + 4 = 8 or 
more) (Table 4).
 Furthermore, the detection rate was investigated ac-
cording to the site at which PCa was detected (Fig. 2). 
The rate of PCa detection with only systematic PBx, 
which did not need target PBx to detect PCa, was 95% 
on the whole, 98% in physician X’s group and 92% in 
physician Y’s group (Fig. 2; A + B + C). There was no 
significant difference between the 2 physicians’ groups. 
However, the detection rate of PCa which was detectable 
only by a target PBx was significantly different between 
the physicians’ groups. 
 Interestingly enough, in the 89 PCa patients with 
target PBx (Fig. 2; B + C + D), PCa was detected also 
in one lobe contralateral to the other lobe that had a sus-
pected cancer lesion on MRI or TRUS in approximately 
20% (18/89). Of the 18 patients, 5 (28%) were diagnosed 
with high GS (4 + 4 = 8 or more), and in 3 of the 5 pa-
tients, target PBx did not detect PCa.
 
DISCUSSION
Urologists have been continuing to explore the optimal 
methodologies to improve the detection rate of PCa with 
PBx. The addition of anterior directed biopsy cores,11 
saturation biopsy templates12, 13 and transperineal tem-
plate-guided biopsy14 has been attempted. Although all 
of these methodologies added some diagnostic useful-
ness, some reports denied the usefulness of these meth-
odologies. The reason the PCa detection rate does not 
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improve dramatically is probably related to the fact that 
these methodologies ultimately remain dependent on 
random sampling. 
 On the other hand, the MRI/US fusion PBx system 
has appeared as a more advanced method of PBx. Pint 
et al. reported that PCa was detected in 12 of 43 (27.9%), 
26 of 39 (66.7%) and 17 of 19 (89.5%) patients with low, 
moderate and high suspicion on MRI, respectively. They 
suggested that their methodology might be useful in fo-
cal therapy for PCa.9 Moreover, they reported in their 
current study that the diagnostic yield of MRI/US fusion 
PBx was not affected by the increased number of prior 
negative PBx procedures, especially for the detection 
of high-grade PCa.10 Certainly, their outcome of fusion 
PBx exceeded that of the past methodology. However, 
this system is not likely to immediately spread world-
wide because the system is very expensive, and focal 
therapy is not standard therapy worldwide. Therefore, 
the methodology adopted in the present study was the 
most common and economical, since it uses the most 
widely available imaging modalities, TRUS and MRI. 
 In the present study, the overall detection rate of 
PCa, including both patients with and without target 
PBx, was almost equivalent to past studies. In patients 
with a suspected lesion on the imaging modalities, 
especially MRI, there was a tendency for the rate of 
cancer detection to be higher. However, the detection 
rate of patients with a suspected lesion on TRUS was 
significantly different between the 2 physician groups. 
This was thought to be due to variation in judging the 
imaging findings on TRUS between the 2 physicians. 
Evaluated exclusively on the outcome of target PBx, the 
overall rate of cancer detection (32%) was not as high as 
we had expected; the cancer detection rate of target PBx 
of a suspected lesion seen only on TRUS was very low 
(8%). This suggests that the evaluation of imaging find-
ings on TRUS was poorly reproducible. Interestingly, the 
cancer detection rate of target PBx of a suspected lesion 
on both MRI and TRUS was increased in all groups, 
and that of Physician Y’s group was higher (73%). How-
ever, there was a significant difference between the 2 
physician groups, likely due to the difference in the hit 
probability to the suspected lesion in target PBx between 
the 2 physicians and the small number of patients in 
this study. Comparing the outcomes of systematic PBx 
and target PBx, the GS was upgraded in 13% of cancer 
patients; thus, more accurate risk classification was ob-
tained in approximately 1 in 10 patients by performing a 
target PBx. It was found that minute cancer with a high 
GS, which was detectable only by a target PBx, was not 
uncommon. Furthermore, in the evaluation according to 
the site from which PCa was detected, since 95% of the 
overall patients in whom PCa was detected did not need 
target PBx, it must be said that target PBx was not useful 
in terms of improvement of cancer detection. Shigemura 
et al.7 reported that, by using the PBx methodology as 
in the present study, only 1 of the 96 patients (1.04%) 
with additional cores based on MRI findings had a 
cancer-positive core that would have been missed by the 
standard 12-core PBx, suggesting that additional PBx 
could be omitted. Singh et al.8 also stated that 3-T MRI-
targeted PBx showed similar PCa detection compared 
to systematic PBx. The present outcome supports these 
conclusions. Moreover, it was also confirmed that the 
overall cancer detection rate was not affected by the dif-
ference in physicians. However, the hit probability of tar-
get PBx was significantly different between the two phy-
sicians, although the cancer detection rate of target PBx 
was not so high as to suggest the usefulness of target 
PBx. PCa was also detected in approximately 20% from 
one lobe without a suspected cancer lesion contralateral 
to the other lobe with a suspected cancer lesion on MRI 
or TRUS; although the probability was low, patients with 
a high GS PCa were included. Summarizing the above 
data, although the probability of PCa in a suspected le-
sion identified on imaging, especially MRI, is high, ow-
ing to the lack of reproducibility and the difference in hit 
probability of the suspected lesion between physicians 
in target PBx without using an MRI/US fusion system, 
there is a limit to the improvement of the cancer detec-
tion rate. 
 Then the question becomes, “Is the target PBx with-
out using MRI/US fusion system completely meaning-
less?” as Shigemura said.7 Certainly, target PBx without 
using an MRI/US fusion system might not be useful 
from the perspective of improving the cancer detec-
tion rate. However, it can be immediately implemented 
in many institutions and may facilitate more accurate 
staging with detection of minute cancer with a high GS. 
Therefore, target PBx of a suspected cancer lesion seen 
on both MRI and TRUS should be carried out, since the 
probability of the existence of cancer is expected to be 
high.
 Furthermore, an ink mark was placed on the rectal, 
prostatic fascia side of the biopsy cores to estimate the 
distance of the cancer lesion from the prostatic fascia. 
This information was used to determine the nerve-
sparing policy more oncologically in robotic-assisted 
laparoscopic radical prostatectomy, sparing as much 
nerve as possible while maintaining the radical cure of 
the cancer. Such small efforts do not improve the cancer 
detection rate, but may improve treatment outcomes. 
  This study has several limitations. Without the 
evaluation of whole mount prostatectomy specimens, the 
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difference in accuracy between target PBx and system-
atic PBx cannot be determined. The MRI system, 1.5-
T or 3.0-T, was not unified because some of the patients 
who visited our hospital from distant places underwent 
MRI at another hospital. The cancer detection rate of 
target PBx might be better if more cores were obtained 
from the suspected lesion. However, because the com-
plication rate may increase with the core number, the 
principle of taking only one core from a suspected lesion 
was adopted. There were no serious complications that 
resulted in the need to extend the duration of scheduled 
hospitalization (data not shown).
 In conclusion, the addition of target PBx of suspect-
ed cancer lesions detected by MRI and/or TRUS to a 
systematic 14-core initial PBx might not be useful from 
the perspective of improving the cancer detection rate 
regardless of operator differences. However, it can be 
immediately implemented in many institutions and may 
make it possible to achieve more accurate risk classifi-
cation with detection of minute cancer with a high GS. 
Moreover, by adding a little ingenuity as ink application, 
it may be useful for determination of treatment policy. 
The authors declare no conflict of interest.
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